公开(公告)号：US20240345100A1

公开(公告)日：2024-10-17

申请号：US18699078

申请日：2022-08-11

申请人： INNOBATION BIO CO., LTD.

发明人： Seung Koo KIM ,  Ki Tae KIM

IPC分类号： G01N33/68 ,  G01N30/02 ,  G01N30/88 ,  G01N33/92

CPC分类号： G01N33/6893 ,  G01N30/88 ,  G01N33/6848 ,  G01N33/92 ,  G01N2030/027 ,  G01N2030/884 ,  G01N2333/4716

摘要： The present invention relates to biomarkers for cancer diagnosis and uses thereof, and more particularly to a composition for diagnosing or predicting cancer prognosis, comprising an agent for measuring levels of at least two biomarkers selected from the group consisting of Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG) and Osteopontin in blood, and a method of using the biomarker to provide information about the diagnosis or prognosis of cancer.
In the present invention, it was confirmed that the level of complement component 7 (C7), dodecanoyl-L-carnitine (DC), lysophosphatidylcholine (LPC), histidine-rich glycoprotein (HRG), and/or osteopontin (OPN) in blood of lung and/or hepatic cancer patients has been found to have different patterns than that of normal individuals, and the combination of these markers has been shown to improve the diagnosis of various cancers, including lung or hepatic cancer. Accordingly, the biomarkers of the present invention can be useful in cancer diagnosis and prognosis.

公开(公告)号：US12109519B2

公开(公告)日：2024-10-08

申请号：US16900682

申请日：2020-06-12

申请人： Utah Valley University

发明人： Timothy Edwin Doyle

IPC分类号： B01L3/00 ,  A61B5/00 ,  A61B5/08 ,  A61B5/1468 ,  A61B5/1477 ,  A61M15/00 ,  A61M15/02 ,  A61M16/10 ,  A62B23/02 ,  B01D39/16 ,  B01F23/00 ,  B01F23/41 ,  B01F101/23 ,  B23Q17/24 ,  C07K14/705 ,  C12M1/34 ,  C12Q1/04 ,  C12Q1/18 ,  C12Q1/686 ,  G01N21/3577 ,  G01N21/359 ,  G01N21/39 ,  G01N21/45 ,  G01N21/64 ,  G01N27/414 ,  G01N30/12 ,  G01N30/68 ,  G01N30/70 ,  G01N30/72 ,  G01N30/88 ,  G01N33/00 ,  G01N33/18 ,  G01N33/50 ,  G01N33/53 ,  G01N33/543 ,  G01N33/68 ,  G01N33/74 ,  H10K10/46 ,  H10K85/00 ,  H10K85/20

CPC分类号： B01D39/1623 ,  A61B5/1468 ,  A61B5/1477 ,  A61B5/6803 ,  A61M15/0001 ,  A61M15/02 ,  A61M16/105 ,  A62B23/025 ,  A61B5/082 ,  A61M2205/0244 ,  A61M2205/0294 ,  A61M2205/18 ,  A61M2205/3303 ,  A61M2205/7536 ,  B01D2239/0414

摘要： Disclosed herein is a molecular imprinted protective face mask comprising a supportive structure, a surface material that receives and retains a molecular imprint and that is positioned to contact airborne molecules during use, a molecular imprint of a bioactive molecule wherein an imprinted cavity is at least one of a bioactive molecule with a molecular configuration that captures a specific airborne and/or microdroplet-borne molecule and a protein with a binding site that captures a specific molecule.

公开(公告)号：US12105068B2

公开(公告)日：2024-10-01

申请号：US17244422

申请日：2021-04-29

申请人： CANON KABUSHIKI KAISHA

发明人： Akihiro Taya ,  Hidetaka Kawamura ,  Yutaka Yoshimasa

IPC分类号： G01N30/88 ,  G01N30/86 ,  G06F18/214 ,  G06N3/04 ,  G06N3/045 ,  G06N3/08

CPC分类号： G01N30/86 ,  G01N30/88 ,  G06F18/214 ,  G06N3/045 ,  G06N3/08 ,  G01N2030/8804 ,  G01N2030/8895

摘要： Hitherto, preprocessing for separating impurities and calculation processing, for example, a peak splitting method, are required in order to acquire information on test substances from spectral information. An information processing apparatus according to the present invention includes information acquisition means for acquiring quantitative information on a test substance estimated by inputting spectral information on a sample containing the test substance and impurities into a learning model.

公开(公告)号：US12102999B2

公开(公告)日：2024-10-01

申请号：US17417537

申请日：2019-12-27

申请人： ASTRAVEUS

发明人： Jérémie Laurent ,  Vincent Thisse

IPC分类号： B01L3/00 ,  B01F23/00 ,  B01F23/41 ,  B01F101/23 ,  B01L3/02 ,  B23Q17/24 ,  C12M1/34 ,  C12Q1/04 ,  C12Q1/18 ,  C12Q1/686 ,  G01N21/3577 ,  G01N21/359 ,  G01N21/39 ,  G01N21/45 ,  G01N21/64 ,  G01N30/12 ,  G01N30/68 ,  G01N30/70 ,  G01N30/72 ,  G01N30/88 ,  G01N33/00 ,  G01N33/18 ,  G01N33/50 ,  G01N33/543 ,  G01N33/68 ,  G01N35/04 ,  G01N35/10

CPC分类号： B01L3/502715 ,  B01L3/0289 ,  B01L3/50273 ,  B01L2200/0673 ,  B01L2200/0689 ,  B01L2200/141 ,  B01L2300/028 ,  B01L2300/0681 ,  B01L2300/0883 ,  B01L2300/14 ,  B01L2300/1883

摘要： A device for handling a particle suspension, in particular a cell suspension, which includes at least one channel for flowing the particle suspension, a pumping unit configured to move a driving fluid and control element for controlling the pumping unit. Also, a method for handling a particle suspension, which includes flowing the particle suspension in or out of at least one channel using a driving fluid for driving the particle suspension in the channel.

公开(公告)号：US20240319210A1

公开(公告)日：2024-09-26

申请号：US18267469

申请日：2021-12-20

申请人： HUMAN METABOLOMICS INSTITUTE, INC.

发明人： Wei Jia ,  Guoxiang Xie ,  Kejun Zhou

IPC分类号： G01N33/72 ,  G01N30/02 ,  G01N30/72 ,  G01N30/88

CPC分类号： G01N33/728 ,  G01N30/7266 ,  G01N2030/027 ,  G01N2030/8822 ,  G01N2333/9108 ,  G01N2333/96419 ,  G01N2800/085

摘要： Disclosed in the present invention is an application of conjugated bilirubin as a biomarker in preparation of a diagnosis device for evaluating a risk of neonatal biliary atresia. Also disclosed in the present invention are a bilirubin content measurement method, a stable quantitative detection reagent for bilirubin, and an application of the quantitative detection reagent for bilirubin in preparation of a kit for measuring a content of the bilirubin and evaluating a risk of biliary atresia of a subject, infant hepatitis syndrome, α1 antitrypsin deficiency disease or Alagille syndrome. Also disclosed in the present invention are a kit for measuring the content of the bilirubin or evaluating the risk of neonatal biliary atresia, an application of the kit, a method for evaluating the risk of neonatal biliary atresia, and a device for predicting the risk of neonatal biliary atresia by using an expression level of the conjugated bilirubin. The present invention has the advantages of being simple and rapid, flexible in sample preparation, low in limit of detection, good in repeatability and high in sensitivity; and the sample preparation and detection method is simple and easy to implement, low in cost and suitable for popularization and use.

公开(公告)号：US12097499B2

公开(公告)日：2024-09-24

申请号：US18151011

申请日：2023-01-06

申请人： Tokitae LLC

发明人： Toan Huynh ,  Bernhard Hans Weigl ,  Samantha A. Byrnes ,  Kevin Paul Flood Nichols

IPC分类号： B01L3/00 ,  B01F23/00 ,  B01F23/41 ,  B01F101/23 ,  B23Q17/24 ,  C12M1/34 ,  C12Q1/04 ,  C12Q1/18 ,  C12Q1/6816 ,  C12Q1/686 ,  C23C2/00 ,  G01N21/3577 ,  G01N21/359 ,  G01N21/39 ,  G01N21/45 ,  G01N21/64 ,  G01N30/12 ,  G01N30/68 ,  G01N30/70 ,  G01N30/72 ,  G01N30/88 ,  G01N33/00 ,  G01N33/18 ,  G01N33/50 ,  G01N33/543 ,  G01N33/68 ,  G01N35/04 ,  G01N35/10

CPC分类号： B01L3/5082 ,  C12Q1/6816 ,  C23C2/51 ,  B01L2200/18 ,  B01L2300/0663 ,  B01L2300/0832 ,  B01L2400/0433 ,  G01N33/18

摘要： An embodiment of a system includes a compartment-generating device, a compartment detector, and electronic computing circuitry. The device is configured to generate compartments of a digital assay, at least one of the compartments having a respective volume that is different from a respective volume of each of at least another one of the compartments. The detector is configured to determine a number of the compartments each having a respective number of a target that is greater than a threshold number of the target. And the electronic circuitry is configured to determine a bulk concentration of the target in a source of the sample in response to the determined number of compartments. Because such a system can be configured to estimate a bulk concentration of a target in a source from a polydisperse digital assay, the system can be portable, and lower-cost and faster, than conventional systems.

公开(公告)号：US12078622B2

公开(公告)日：2024-09-03

申请号：US17697364

申请日：2022-03-17

申请人： SHIMADZU CORPORATION

发明人： Yukihiko Kudo

IPC分类号： G01N30/72 ,  G01N30/86 ,  G01N30/88 ,  G01N30/02 ,  G01N30/04 ,  G01N30/62

CPC分类号： G01N30/7206 ,  G01N30/8634 ,  G01N30/8668 ,  G01N30/8679 ,  G01N30/88 ,  G01N2030/025 ,  G01N2030/047 ,  G01N2030/626 ,  G01N2030/8804 ,  G01N2030/8845

摘要： In a quantitative determination device 10 for brominated flame-retardant compounds, a storage section 41 holds a relative response factor 411 representing a relationship of a measured intensity of a compared compound to that of a reference compound selected from target compounds. A standard-sample measurer 43 acquires the intensity of the reference compound by measuring a standard sample, using an analyzer 10, 20. A target-sample measurer 45 acquires the intensities of the reference and compared compounds by measuring a target sample, using the analyzer. A reference-compound quantity determiner 46 determines a quantitative value of the reference compound in the target sample. A compared-compound quantity determiner 47 determines a quantitative value of the compared compound based on the quantity of the reference compound in the standard sample, intensity of the reference compound acquired by the standard-sample measurer, intensity of the compared compound acquired by the target-sample measurer, and relative response factor of the compared compound.

公开(公告)号：US20240288409A1

公开(公告)日：2024-08-29

申请号：US18571782

申请日：2022-06-20

申请人： CRESCENDO CARE S.R.L.

发明人： Francesco Chiara ,  Simona Roggero

IPC分类号： G01N30/88 ,  G01N30/02 ,  G01N30/06 ,  G01N30/72

CPC分类号： G01N30/88 ,  G01N30/06 ,  G01N30/72 ,  G01N2030/027 ,  G01N2030/062 ,  G01N2030/8818 ,  G01N2030/8822 ,  G01N2030/8827

摘要： The present invention relates to a multiresidual method for detecting and/or quantifying at least one amino acid or derivative thereof, at least one organic acid, and/or at least one modified nucleotide, in a sample of biological liquid or circulating cells, comprising the steps of: a) treating the sample with an extraction mixture at room temperature, preferably refrigerated at a temperature lower than −20° C., comprising i) a mixture of one or more organic solvents having a final polarity index between 3 and 6, ii) a strong acid in an amount sufficient for the extraction mixture to have a normality from 0.005 to 0.025 N or a weak acid with ka in the range between 3.5×10−7 and 7.0×10−3 with a final concentration in the extraction mixture from 5 to 30 mM; wherein the extraction mixture comprises: acetonitrile, dichioromethane and formic acid; or acetonitrile and hydrochloric acid; or acetone and formic acid; or methanol and formic acid; or acetonitrile and formic acid; or methanol and dimethyl sulfoxide; or acetonitrile and dimethyl sulfoxide; or acetonitrile, methanol and hydrochloric acid; or acetonitrile and methanol; b) performing a hydrophilic interaction liquid chromatography (HILIC) on the sample treated in step a); c) performing an analysis by tandem mass spectrometry on the sample obtained in step b) detecting and/or quantifying the at least one amino acid or derivative thereof, and/or the at least one organic acid, and/or the at least one modified nucleotide.

公开(公告)号：US20240264048A1

公开(公告)日：2024-08-08

申请号：US18617574

申请日：2024-03-26

申请人： Entech Instruments Inc.

发明人： Daniel B. CARDIN

IPC分类号： G01N1/22 ,  G01N1/40 ,  G01N30/00 ,  G01N30/16 ,  G01N30/60 ,  G01N30/88

CPC分类号： G01N1/2202 ,  G01N1/405 ,  G01N30/16 ,  G01N30/6078 ,  G01N30/88 ,  G01N2030/008 ,  G01N2030/0095 ,  G01N2030/8804

摘要： A hybrid trap including a replaceable open-tubular capillary trap followed by a packed trap is used to collect, preconcentrate, and recover a sample, such as VOCs and SVOCs found in air. The capillary stage prevents losses and carryover of the heavy fraction and can also collect the particles in air that contain the heavier SVOCs, also preventing them from reaching the packed stage. The packed stage traps lighter organic compounds that are not as prone to carryover due to channeling. The ionic species within the collected VOCs and SVOCs at the capillary trap can be converted to volatile compounds that allow gas chromatography-mass spectrometry.

公开(公告)号：US20240255511A1

公开(公告)日：2024-08-01

申请号：US18564640

申请日：2022-05-27

申请人： HUMAN METABOLOMICS INSTITUTE, INC.

发明人： Wei Jia ,  Guoxiang Xie ,  Tianlu Chen

IPC分类号： G01N33/574 ,  G01N30/02 ,  G01N30/72 ,  G01N30/88

CPC分类号： G01N33/57438 ,  G01N30/7233 ,  G01N30/88 ,  G01N2030/027 ,  G01N2030/8822 ,  G01N2570/00

摘要： Provided in the present invention is a device for diagnosing liver cancer. The device determines the level of a biomarker in a biological sample of a subject to be a diagnostic indicator, wherein the level of the biomarker is selected from the level of one or more of taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenodeoxycholic acid, linolelaidic acid (C18:2n6t), maltotriose, maltose and/or lactose, α-linolenic acid, β-alanine, sebacic acid, 2-methylvaleric acid, valeric acid, isovaleric acid and hexanoic acid, and/or the ratio of secondary bile acid to primary bile acid, and/or the ratio of glycine-conjugated primary bile acid to taurine-conjugated primary bile acid, the primary bile acid being selected from cholic acid and chenodeoxycholic acid, and the secondary bile acid comprising deoxycholic acid, lithocholic acid and ursodeoxycholic acid. The diagnosis device of the present invention can be used for early diagnosis of liver cancer and liver cirrhosis, thereby buying time for patients and improving the clinical treatment effect.